| Ytd | -14.91% | |
| 1y | -2.62% |
| Open | 3.67 | Prev Close | 3.53 | Low | 3.52 | High | 3.70 | Mkt Cap | 135.35M |
| Vol | 134.00 | Avg Vol | 1.29K | EPS | -1.71 | P/E | N/A | Forward P/E | -2.96 |
| Beta | 1.11 | Short Ratio | 4.49 | Inst. Own | 5.31% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-25 | 50-d Avg | 4.12 | 200-d Avg | 4.20 | 1yr Est | 10.37 |
MOLN News
Molecular Partners (NASDAQ:MOLN) reported quarterly losses of $(0.89) per share which missed the ana
Randomized Phase 2 study in front-line setting progressing well, with nine sites actively recruiting
Developing bispecific Radio-DARPins to engage multiple tumor targets simultaneously, improving preci
Phase 1/2a trial of MP0712, 212Pb-based DLL3-targeted Radio-DARPin co-developed with Orano Med: Dosi
Five sites recruiting in US study of DLL3-targeting 212Pb-labelled Radio-DARPin MP0712Dosing ongoing
Molecular Partners (NASDAQ:MOLN) reported quarterly losses of $(0.45) per share which missed the ana
MP0317 is designed to activate immune cells specifically within the TME by anchoring to fibroblast a
HC Wainwright & Co. analyst Robert Burns reiterates Molecular Partners (NASDAQ:MOLN) with a B
MP0632 nominated as first logic-gated Switch-DARPin T cell engager candidate for the treatment of MS
Highly comparable biodistribution profiles of Radio-DARPin candidates labeled with imaging isotopes
HC Wainwright & Co. analyst Robert Burns reiterates Molecular Partners (NASDAQ:MOLN) with a B
Molecular Partners (NASDAQ:MOLN) reported quarterly losses of $(0.41) per share which missed the ana
Specific tumor accumulation and attractive biodistribution highly supportive of MP0712 clinical deve
HC Wainwright & Co. analyst Robert Burns initiates coverage on Molecular Partners (NASDAQ:MOL
Phase 1/2a study with lead Radio-DARPin MP0712 initiated; first patient dosing expected Q1 2026, ini
JP Morgan analyst Richard Vosser maintains Molecular Partners (NASDAQ:MOLN) with a Neutral and lo
Poster outlines clinical benefit with acceptable safety profile across 9 tested dosing regimensAccel
Case study with first patient images of half-life engineered MP0712 from compassionate care use show
Companies Reporting Before The Bell • Pharming (NASDAQ:PHAR) is projected to report earnings for it
On Thursday, 283 companies set new 52-week lows.
Companies Reporting Before The Bell • Aurora Mobile (NASDAQ:JG) is expected to report earnings for
On Tuesday, 400 companies set new 52-week lows.
On Thursday, 529 companies set new 52-week lows.
On Tuesday, 250 stocks hit new 52-week lows.
On Monday, 273 companies set new 52-week lows.
During Wednesday's trading, 435 companies set new 52-week lows.
Tuesday's session saw 211 companies set new 52-week lows.
During Thursday, 849 stocks hit new 52-week lows.